METHOD OF TREATING SECONDARY MITOCHONDRIAL DYSFUNCTION IN CHILDREN SUFFERING URINOGENITAL PATHOLOGIES Russian patent published in 2015 - IPC A61K31/205 G01N33/50 A61P3/00 

FIELD: medicine.

SUBSTANCE: treating secondary mitochondrial dysfunction in the children suffering an urinogenital pathology is ensured by measuring a pre-therapeutic level of reactive oxygen intermediate (ROI) generation by whole capillary blood leukocytes by luminol-dependent chemoluminescence stimulated by barium sulphate crystals and antioxidant activity (AOA) of serum by chemiluminescence activated by rhodamine B in the presence of ferrous iron ions. If ROI is more than 2.7×10⁵ quantum/sec × 4π, AOA is less than 29 relative units, an energotropic therapy is prescribed in the form of oral administration of 30% carnitine 30 mg/kg/day for one month; thereafter ROI and AOA is re-measured. If ROI is less than 2.7×10⁵ quantum/sec × 4π, AOA is more than 29 relative units, the treatment is terminated; if ROI is more than 2.7×10⁵ quantum/sec × 4π, and AOA is less than 29 relative units, continuing the carnitine therapy is indicated in the same dose for another month.

EFFECT: invention enables optimising the drug-induced treatment of secondary mitochondrial dysfunction in the children with congenital urogenital abnormalities by the individual approach, and grounds prescribing the energotropic therapy and its length.

3 tbl, 2 ex